Related Experiment Video

Updated: Nov 29, 2025

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

3.0K

Clinical impact of EZH2 and its antagonist SMARCA4 in ovarian cancer

Katharina Leitner1, Irina Tsibulak1, Verena Wieser1

  • 1Department of Obstetrics and Gynecology, Innsbruck Medical University, Anichstraße 35, 6020, Innsbruck, Austria.

Scientific Reports
|November 24, 2020
PubMed

Insights

High SMARCA4 expression in ovarian cancer correlates with better survival. Moderate to high EZH2 expression predicts poor outcomes, but ultra-high levels indicate favorable survival in a specific subgroup.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • SMARCA4 and EZH2 proteins are key regulators of chromatin remodeling complexes SWI/SNF and PRC2, respectively.
  • Dysregulation of these complexes is implicated in cancer development and progression.
  • EZH2 inhibitors are being explored as cancer therapeutics to shift the balance towards differentiation.

Purpose of the Study:

  • To investigate the prognostic significance of SMARCA4 and EZH2 mRNA expression in epithelial ovarian cancers (OCs).
  • To correlate their expression levels with clinico-pathological parameters and patient survival outcomes.

Main Methods:

  • Quantitative real-time PCR (RT-PCR) was used to assess SMARCA4 and EZH2 mRNA expression in 238 epithelial ovarian cancer samples.
  • Optimal expression thresholds were determined using Youden's index and receiver operating characteristic (ROC) curves.
  • Cox regression analysis was employed to evaluate the association between gene expression and patient survival (progression-free survival and overall survival).

Main Results:

  • High SMARCA4 mRNA expression was independently associated with favorable progression-free survival (PFS) and overall survival (OS).
  • EZH2 mRNA expression above the 29th percentile independently predicted poor PFS.
  • However, EZH2 mRNA levels above the 94th percentile showed a significant conversion to favorable PFS and OS.

Conclusions:

  • SMARCA4 expression is a favorable prognostic marker in ovarian cancer.
  • EZH2 expression has a dual prognostic role: moderate/high levels indicate poor outcome, while ultra-high levels predict favorable survival.
  • The ultra-high EZH2 subgroup exhibits REV7-abrogated platinum hypersensitivity and PARP-inhibitor resistance, suggesting distinct therapeutic vulnerabilities.

More Related Videos

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

12.6K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.6K

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.3K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.2K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.2K